Top

Published in:

01-12-2018 | Original Scientific Report

Prognostic Value of Trefoil Factor 3 Expression in Patients with Gastric Cancer

Authors: Yoshiki Taniguchi, Yukinori Kurokawa, Tsuyoshi Takahashi, Jota Mikami, Yasuhiro Miyazaki, Koji Tanaka, Tomoki Makino, Makoto Yamasaki, Kiyokazu Nakajima, Masaki Mori, Yuichiro Doki

Published in: World Journal of Surgery | Issue 12/2018

Abstract

Background

Trefoil factor 3 (TFF3) is a small molecule secreted by the mammalian gastrointestinal tract and is overexpressed in some human malignant tumors. We investigated the prognostic values of immunohistochemical (IHC) TFF3 expression and serum TFF3 levels in patients with gastric cancer, and whether TFF3 influenced tumor proliferation and invasion in vitro.

Methods

We examined 111 patients who underwent R0 gastrectomy for gastric cancer between April 2012 and April 2015. IHC TFF3 expression and serum TFF3 levels were evaluated regarding their associations with clinicopathological factors and recurrence-free survival (RFS). In vitro cell proliferation and migration assays were used to explore the biological role of TFF3 in human gastric cancer cell lines following transfection with a lentivirus-based shRNA plasmid.

Results

IHC TFF3 expression showed significant associations with depth of invasion (p = 0.024), lymph node metastasis (p = 0.008), and RFS (log-rank p = 0.002). Serum TFF3 levels were correlated with IHC TFF3 expression (p = 0.013). RFS was significantly poorer in patients with high (n = 27) compared to low (n = 84) serum TFF3 levels (log-rank p = 0.003). Cox multivariate analysis indicated that serum TFF3 level was an independent prognostic factor for RFS (p = 0.024). In vitro assays, TFF3 downregulation significantly inhibited both proliferation and invasion of gastric cancer cells.

Conclusions

Serum TFF3 levels could be useful prognostic markers in patients with gastric cancer. TFF3 may play various biological roles in proliferation and invasion of gastric cancer cells.

Available only for authorised users

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRef

Colvin H, Mizushima T, Eguchi H et al (2017) Gastroenterological surgery in Japan: the past, the present and the future. Ann Gastroenterol Surg 1:5–10CrossRef

Mukai Y, Kurokawa Y, Takiguchi S et al (2017) Are treatment outcomes in gastric cancer associated with either hospital volume or surgeon volume? Ann Gastroenterol Surg 1:186–192CrossRef

Plaut AG (1997) Trefoil peptides in the defense of the gastrointestinal tract. N Engl J Med 336:506–507CrossRef

Ribieras S, Tomasetto C, Rio MC (1998) The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1378:F61–F77PubMed

Kjellev S (2009) The trefoil factor family—small peptides with multiple functionalities. Cell Mol Life Sci 66:1350–1369CrossRef

Wong WM, Poulsom R, Wright NA (1999) Trefoil peptides. Gut 44:890–895CrossRef

Hoffmann W, Jagla W, Wiede A (2001) Molecular medicine of TFF peptides: from gut to brain. Histol Histopathol 16(1):319–334PubMed

Leung WK, Yu J, Chan FK et al (2002) Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 197:582–588CrossRef

10.

Kannan N, Kang J, Kong X et al (2010) Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia 12:1041–1053CrossRef

11.

Perry JK, Kannan N, Grandison PM et al (2008) Are trefoil factors oncogenic? Trends Endocrinol Metabol 19:74–81CrossRef

12.

Huang Z, Zhang X, Lu H et al (2014) Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC Gastroenterol 14:74CrossRef

13.

Aikou S, Ohmoto Y, Gunji T et al (2011) Tests for serum level of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology 141:837–845CrossRef

14.

Im S, Yoo C, Jung JH et al (2013) Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis. Int J Med Sci 10(2):133–140CrossRef

15.

Sugimura K, Fujiwara Y, Omori T et al (2016) Clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids obtained pre- and post-lymphadenectomy from gastric cancer patients. Surg Today 46(6):654–660CrossRef

16.

Guleng B, Han J, Yang JQ et al (2012) TFF3 mediated induction of VEGF via hypoxia in human gastric cancer SGC-7901 cells. Mol Biol Rep 39:4127–4134CrossRef

17.

Podolsky DK, Lynch Devaney K, Stow JL et al (1993) Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 268:6694–6702PubMed

18.

Vestergaard EM, Brynskov J, Ejskjaer K et al (2004) Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel disease. Scand J Clin Lab Invest 64:146–156CrossRef

19.

Wright NA, Poulsom R, Stamp G et al (1993) Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 104:12–20CrossRef

20.

Xue H, Lü B, Zhang J et al (2010) Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 9:545–555CrossRef

21.

Qu Y, Yang Y, Ma D et al (2012) Increased trefoil factor 3 level in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep 27:1277–1283CrossRef

22.

Bignotti E, Ravaggi A, Tassi RA et al (2008) Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer 99:768–773CrossRef

23.

Vestergaard EM, Borre M, Poulsen SS et al (2006) Plasma level of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 12:807–812CrossRef

24.

Perry JK, Kannan N, Grandison PM et al (2008) Are trefoil factors oncogenic? Trends Endocrinol Metab 19:74–81CrossRef

25.

Xiao L, Liu YP, Xiao CX et al (2014) Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers. BMC Clin Pathol 14:26CrossRef

26.

Lau WH, Pandey V, Kong X et al (2015) Trefoil factor-3 (TFF3) stimulates de novo angiogenesis in mammary carcinoma both directly and indirectly via IL-8/CXCR2. PLoS ONE 10(11):e0141947. https://doi.org/10.1371/journal.pone.0141947 CrossRefPubMedPubMedCentral

27.

Rivat C, Rodrigues S, Bruyneel E et al (2005) Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)—and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 65:195–202PubMed

28.

Sun Z, Liu H, Yang Z et al (2014) Intestinal trefoil factor activates the PI3K/Akt signaling pathway to protect gastric mucosal epithelium from damage. Int J Oncol 45:1123–1132CrossRef

29.

Fresno Vara JA, Casado E, de Castro J et al (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193–204CrossRef

30.

Buda A, Jepson MA, Pignatelli M (2012) Regulatory function of trefoil peptides (TFF) on intestinal cell junctional complexes. Cell Commun Adhes 19:63–68CrossRef

31.

Lee JY, Park KS, Lee HG et al (2016) Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer. Clin Exp Med. https://doi.org/10.1007/s10238-016-0426-1 CrossRefPubMed

32.

Yu Y, Jin H, Holder D et al (2010) Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 28(5):470–477CrossRef

33.

Roa GJB, Tortolero GS, Gonzalez JE (2013) Trefoil factor 3 (TFF3) expression is regulated by insulin and glucose. J Health Sci 3:1–12CrossRef

Title: Prognostic Value of Trefoil Factor 3 Expression in Patients with Gastric Cancer
Authors: Yoshiki Taniguchi
Yukinori Kurokawa
Tsuyoshi Takahashi
Jota Mikami
Yasuhiro Miyazaki
Koji Tanaka
Tomoki Makino
Makoto Yamasaki
Kiyokazu Nakajima
Masaki Mori
Yuichiro Doki
Publication date: 01-12-2018
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 12/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-018-4737-0

At a glance: The STEP trials

Springer Medicine

Prognostic Value of Trefoil Factor 3 Expression in Patients with Gastric Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2018

Liver Regeneration is Preserved After At Least Four Repeated Liver Resections for Hepatocellular Carcinoma

Discrimination, Bullying and Harassment in Surgery: A Systematic Review and Meta-analysis

The Impact of Preoperative Hemoglobin Level on the Short-Term Outcomes After Living Donor Liver Transplantation

Authors’ Reply: Risk Factors for Mortality and Morbidity in Elderly Patients Presenting with Digestive Surgical Emergencies

Author’s Reply: Management of Enterocutaneous Fistula: Outcomes in 276 Patients

Magnetic Anastomosis for Biliojejunostomy: First Prospective Clinical Trial